Plaintiffs in the Risperdal lawsuit claim that Johnson & Johnson improperly marketed the antipsychotic drug and misrepresented the side effects. Plaintiffs claim that Risperdal caused them to develop a condition called gynecomastia -- the development of female breast on males.

As of September 24, 2018, there are 6,771 cases filed in the First Judicial Circuit of Pennsylvania Court of Common Pleas Complex Litigation Center. According to Johnson & Johnson's 2017 10-K filed with the SEC, there are 13,700 pending Risperdal claims.

Latest Cases

Read about the most recent cases in the Risperdal tort»

Public Records

View public records and evidence in the Risperdal tort»

Reporting

Read news reports on the Risperdal cases»

Yount v. Janssen

October 2016

Result: $76.6 million Judgment

In addition to answering questions about negligence and causation, the jury in the Yount case was asked if defendants did “intentionally falsify, destroy or conceal records containing material evidence in this case?” The jury answered “yes,” and awarded the plaintiff $70 million. Later, Judge Paula A. Patrick issued a judgment order adding $6.66 million in delay damages.

Public Records:

Complaint

Verdict

Judgment Order

Defendant's Notice of Appeal

Plaintiff's Notice of Cross-Appeal

Press Reports:

Judge Urges Pa. Superior Court to Affirm $70M Risperdal Verdict | law.com | June 22, 2018

Judge Tacks $6M In Delay Damages To $70M Risperdal Award | Law360.com | August 12, 2016

Johnson & Johnson Hit With $70M Risperdal Verdict | bna.com | July 6, 2016

J&J must pay $70 million to male teen who took Risperdal and developed large breasts | statnews.com | July 5, 2016

J&J's Janssen hit with $70 million verdict in Risperdal trial | Reuters | July 1, 2016